The Comparative Effectiveness of Carvedilol Versus Other Nonselective β-Blockers in Cirrhosis.

Authors

Tracey G Simon, Yichi Zhang, Anna Kehoe, Raymond T Chung, Kueiyu Joshua Lin

Published in

Annals of internal medicine. Jul 07, 2026. Epub Jul 07, 2026.

Abstract

In cirrhosis, nonselective β-blockers (NSBBs; carvedilol, nadolol, and propranolol) reduce hepatic portal pressure and have demonstrated benefit versus placebo for preventing decompensation. Although carvedilol has emerged as the preferred NSBB, direct evidence remains limited about its effectiveness for preventing decompensation and death versus other NSBBs.
To compare the effectiveness of carvedilol versus nadolol versus propranolol in cirrhosis.
Database cohort study.
A U.S. administrative claims database, Optum Clinformatics Data Mart (2013 to 2025).
Adults with cirrhosis initiating carvedilol, nadolol, or propranolol.
The primary outcome was a composite of hospitalization for major decompensation (ascites, spontaneous bacterial peritonitis [SBP], hepatorenal syndrome [HRS], hepatic encephalopathy, or variceal hemorrhage). Absolute risk differences (RDs) and risk ratios (RRs) at 6 months of follow-up were estimated using inverse probability of treatment weighting accounting for 129 preexposure covariates.
Carvedilol initiators had meaningfully lower 6-month risk for major decompensation events compared with nadolol (RD, -3.69 percentage points [95% CI, -5.33 to -2.09 percentage points]; RR, 0.80 [CI, 0.72 to 0.88]) or propranolol (RD, -2.88 percentage points [CI, -4.29 to -1.49 percentage points]; RR, 0.83 [CI, 0.76 to 0.90]). This included substantially lower 6-month risk for specific decompensation events with carvedilol compared with nadolol or propranolol, including reduced risk for variceal hemorrhage (RDs, -3.51 percentage points [CI, -4.79 to -2.20 percentage points] and -1.65 percentage points [CI, -2.71 to -0.59 percentage points], respectively) and ascites, SBP, or HRS (RDs, -3.05 percentage points [CI, -4.52 to -1.75 percentage points] and -1.58 percentage points [CI, -2.77 to -0.44 percentage points], respectively).
Nonrandomized treatment selection.
Among U.S. patients with cirrhosis, carvedilol initiation-as opposed to nadolol or propranolol-was associated with meaningfully lower rates of major decompensation events.
National Institutes of Health.

PMID:
42407069
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.